|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:1987
gptkb:FDA
|
|
gptkbp:available_on
|
gptkb:Software_Solutions
gptkb:tablet
gptkb:capsule
|
|
gptkbp:brand
|
gptkb:Retrovir
|
|
gptkbp:casnumber
|
30516-87-1
|
|
gptkbp:chemical_formula
|
C10 H13 N5 O4 S
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
phosphorylation
azidation
|
|
gptkbp:contraindication
|
severe liver disease
bone marrow suppression
hypersensitivity to AZT
|
|
gptkbp:developed_by
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discovered_by
|
gptkb:1980s
|
|
gptkbp:drug_interactions
|
gptkb:didanosine
gptkb:stavudine
gptkb:zidovudine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
azidothymidine (AZT)
|
|
gptkbp:impact_on_life_expectancy
|
increased for HIV patients
|
|
gptkbp:invention
|
gptkb:2005
|
|
gptkbp:lifespan
|
1 hour
|
|
gptkbp:marketed_as
|
gptkb:Retrovir
|
|
gptkbp:mechanism_of_action
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:pharmacokinetics
|
bioavailability 60-70%
|
|
gptkbp:research_focus
|
AIDS research
HIV treatment
|
|
gptkbp:route_of_administration
|
oral
intravenous
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
muscle pain
nausea
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:structure
|
nucleoside analog
|
|
gptkbp:treatment
|
with efavirenz
with lamivudine
with tenofovir
|
|
gptkbp:used_for
|
treatment of HIV/ AIDS
|
|
gptkbp:bfsParent
|
gptkb:RNA_Polymerase
|
|
gptkbp:bfsLayer
|
4
|